Molecular Internal Medicine

Endocrinology

Primum non nocere: Why calcitriol («vitamin» D) hormone therapy is not a magic bullet
M. Barton
Arterioscler Thromb Vasc Biol 39, 117-120, 2019

Permissive role for GPER in arterial hypertension
M. Barton, M.R. Meyer
Hypertension 73, e9-e10, 2019


Gender differences in patient and system delay for primary percutaneous coronary intervention: current trends in a Swiss ST-segment elevation myocardial infarction population
M.R. Meyer, A.M. Bernheim, D.J. Kurz, C.J. O'Sullivan, D. Tüller, R. Zbinden, T. Rosemann, F.R. Eberli
Eur Heart J Acute Cardiovasc Care 2019

GPER is required for age-dependent albuminuria and glomerulosclerosis: evidence for its role in podocyte injury and mesangial Nox1 regulation
M.R. Meyer, D. Daniel, C.D. Woods, G. Sharma, N.C. Fredette, K. Amann, M. Barton, E.R. Prossnitz
Hypertension 72 (suppl).:P261, 2018


GPER blockers as Nox downregulators: a new drug class to target chronic non-communicable diseases
M.R. Meyer, M. Barton

J Steroid Biochem Mol Biol 176, 82-87, 2018

Twenty years of G protein-coupled estrogen receptor GPER: historical and personal perspectives
M. Barton, E. J. Filardo, S.J. Lolait, P. Thomas, M. Maggiolini, E.R. Prossnitz
J Steroid Biochem Mol Biol 176, 4-15, 2018

Rapid vasodilation to raloxifene: role of estrogen receptors and off-target effects
M. Barton, E.R. Prossnitz.
Br J Pharmacol 174, 4201-4202, 2017

Paradoxical lack of increase in endothelin-1 levels in obese mice – possible role of endothelin-B receptors
O. Baretella, S.K. Chung, A. Xu, P.M Vanhoutte
Acta Pharmacologica Sinica 38, 1699–1700, 2017

Obesity causes lymphatic vascular injury: time for clinical translation
M. Barton, M. Husmann
J Physiol (Lond) 594, 6807-6808, 2016

Obligatory role for GPER in cardiovascular aging and disease
M.R. Meyer, N.C. Fredette, C. Daniel, G. Sharma, K. Amann, J.B. Arterburn, M. Barton, E.R. Prossnitz.
Science Signaling 9, ra105, 2016

Estrogen signaling in the adrenal cortex: implications for blood pressure sex differences
B. Carrocia, T.M. Seccia, M. Barton, G.P. Rossi
Hypertension 68, 840-848, 2016

Estrogens and coronary artery disease: new clinical perspectives
M.R. Meyer, M. Barton
Adv Pharmacol 77, 307-360, 2016

Not lost in translation: Emerging clinical importance of the G protein-coupled estrogen receptor GPER
M. Barton
Steroids 111, 37-45, 2016

GPER is required for the age-dependent upregulation of the myocardial endothelin system
M.R. Meyer, N.C. Fredette, G. Sharma, M. Barton, E.R. Prossnitz
Life Sci 159, 61-65, 2016


G protein-coupled estrogen receptor inhibits vascular prostanoid production and activity
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
J Endocrinol 227, 61-69, 2015

Erratum: G Protein-coupled estrogen receptor protects from atherosclerosis
M.R. Meyer, N.C. Fredette, T.A. Howard, C. Hu, C. Ramesh, C. Daniel, K. Ammann, J.B. Arterburn, M. Barton, E.R. Prossnitz
Sci Rep 5, 13510, 2015

Nicolaus Copernicus and the rapid vascular responses to aldosterone
M. Barton, M.R. Meyer
Trends Endocrinol Metab 26, 396-398, 2015

Emerging roles of GPER in diabetes and atherosclerosis
M. Barton, E.R. Prossnitz
Trends Endocrinol Metab 26, 185-192, 2015

G Protein-coupled estrogen receptor protects from atherosclerosis
M.R. Meyer, N.C. Fredette, T.A. Howard, C. Hu, C. Ramesh, C. Daniel, K. Ammann, J.B. Arterburn, M. Barton, E.R. Prossnitz.
Sci Rep 4, 7564, 2014

Estrogen biology: New insights on GPER function and clinical opportunities
E.R. Prossnitz, M. Barton
Mol Cell Endocrinol 389, 71-83, 2014

Obesity and heterozygous endothelial overexpression of prepro-endothelin-1 modulate responsiveness of mouse main and segmental renal arteries to vasoconstrictor agents S.K. Chung, M. Barton, A. Xu, P.M. Vanhoutte
Life Sci
118, 206-212, 2014

Alike but not the same: anatomic heterogeneity of estrogen receptor-mediated vasodilation
M. Barton, M.R. Meyer, E.R Prossnitz

J Cardiovasc Pharmacol 62, 22-25, 2013

Regulation of vascular smooth muscle tone by Adipose-Derived Contracting Factor
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
PLoS ONE 8, e79245, 2013

Prevention and endothelial therapy of coronary artery disease
M. Barton
Curr Opin Pharmacol 13, 225-241, 2013

Mechanisms and therapy of atherosclerosis and its clinical complications
M. Barton

Curr Opin Pharmacol 13, 149-153, 2013

Cholesterol and atherosclerosis: Modulation by estrogen
M. Barton

Curr Opin Lipidol 24, 214-220, 2013

Childhood obesity: Preventing today's children from becoming tomorrow's patients
M. Barton

IFAVA Scientific Newsletter 75, 1, 2013

Childhood obesity: a life-long health risk
M. Barton

Acta Pharmacol Sin 33, 189-193, 2012

Obesity and risk of vascular disease: Importance of endothelium-dependent vasoconstriction
M. Barton, O. Baretella, M.R. Meyer
Br J Pharmacol 165, 591-602, 2012

Testosterone and secondary hypertension: New pieces to the puzzle
M. Barton, E.R. Prossnitz, M.R. Meyer

Hypertension 59, 1011-1103, 2012

Position paper: The membrane estrogen receptor GPER - clues and questions
M. Barton

Steroids 77, 925-242, 2012

The G protein-coupled estrogen receptor GPER in physiology and disease
E.R. Prossnitz, M. Barton

Nature Rev Endocrinol 7, 715-726, 2011

Obesity, insulin resistance and diabetes: sex differences and role of estrogens receptors
M.R. Meyer, D.J. Clegg, E.R. Prossnitz, M. Barton
Acta Physiol (Oxf) 203, 259-269, 2011

GPER regulates endothelin-dependent vascular tone and intracellular calcium
M.R. Meyer, A.S. Field, N.L. Kanagy, M. Barton, E.R. Prossnitz
Life Sci 91, 623-627, 2012

Deletion of the G protein-coupled estrogen receptor increases endothelial vasoconstriction
M.R. Meyer, K. Amann, A.S. Field, C. Hu, H.J. Hathyway, N.L. Kanagy, M.K. Walker, M. Barton, E.R. Prossnitz

Hypertension 59, 507-512, 2012

The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function
M.R. Meyer, E.R. Prossnitz, M. Barton

Vascul Pharmacol 55, 17-25, 2011

Estrogen-independent activation of estrogen receptors
M. Barton, M.R. Meyer, E.R. Prossnitz
Hypertension 57, 1056-1057, 2011

GPER/GPR30 and regulation of vascular tone and blood pressure
M.R. Meyer, E.R. Prossnitz, M. Barton

Immunol Endocr Metab Agents Med Chem 4, 255-261, 2011

Obesity and aging: determinants of endothelial cell dysfunction and atherosclerosis
M. Barton
Pflügers Arch 460, 825-837, 2010

Lung cancer and hormone replacement therapy
M. Barton, M.R. Meyer, J.L. Bolton, E.R. Prossnitz
Lancet 375, 117-118, 2010

Übergewicht und kardiovaskuläres Risiko: Neues zu Pathogenese und Therapie
M.R. Meyer, C.A. Meier
Swiss Medical Forum 10, 358-362, 2010

Dilation of epicardial coronary arteries by the G protein-coupled estrogen receptor agonists G-1 and ICI 182,780
M.R. Meyer, O. Baretella, E.R. Prossnitz, M. Barton
Pharmacology 86, 58-64, 2010

Non-genomic regulation of vascular cell function and growth by estrogen
M.R. Meyer, E. Haas, E.R. Prossnitz, M. Barton
Mol Cell Endocrinol 308, 9-16, 2009

Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER
E.R. Prossnitz, M. Barton
Prostaglandins Other Lipid Mediat 89, 89-97, 2009

Getting radical about obesity: new links between fat and heart disease
M. Barton, E. Haas, I. Bhattacharya
Arterioscler Thromb Vasc Biol 29, 447-448, 2009

Postmenopausal hypertension: Mechanisms and therapy
M. Barton, M.R. Meyer
Hypertension 54, 11-18, 2009

ERα, ERβ, and gpER: novel aspects of estrogen receptor signaling in atherosclerosis
M.R. Meyer, M. Barton
Cardiovasc Res 83, 605-610, 2009

Regulatory role of G protein coupled estrogen receptor for vascular function and obesity
E. Haas, I. Bhattacharya, E. Brailoiu, M. Damjanovic, G.C. Brailoiu, X. Gao, L. Mueller-Guerre, A. Gut, R. Minotti, M.R. Meyer,
K. Amann, E. Ammann, A. Perez-Dominguez, M. Genoni, D.J. Clegg, N.J. Dun, T.C. Resta, E.R. Prossnitz, M. Barton
Circ Res 104, 288-291, 2009

Regional heterogeneity of functional changes in conduit arteries after high-fat diet
I. Bhattacharya, A.L. Mundy, C.C. Widmer, M. Kretz, M. Barton
Obesity (Silver Spring) 16, 743-748, 2008

Fat intake and cardiovascular response
M. Damjanovic, M. Barton
Curr Hypertens Rep 10, 25-31 2008

Distinct roles of estrogen receptors α and β mediating acute vasodilatation of epicardial coronary arteries
T. Traupe, C.D. Stettler, H. Li, E. Haas, I. Bhattacharya, R. Minotti, M. Barton
Hypertension 49, 1364-1370, 2007

Differential effects of 17β-estradiol on function and expression of estrogen receptor α, estrogen receptor β, and GPR30 in arteries and veins of patients with atherosclerosis
E. Haas, M.R. Meyer, U. Schurr, I. Bhattacharya, R. Minotti, H.H. Nguyen, A. Heigl, M. Lachat, M. Genoni, M. Barton
Hypertension 49, 1358-1363, 2007

WISDOM trial, postmenopausal hormone replacement and cardiovascular events: Why it is still not wise to use equine estrogens
M. Barton, M.R.Meyer, I. Bhattacharya, E. Haas
Br Med J Rapid Response, e-pub August 28, 2007

Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits?
M. Barton, M.R. Meyer, E. Haas
Arterioscler Thromb Vasc Biol 27, 1669-1672, 2007

Effects of obesity on mortality in patients with unstable angina or non ST-elevation myocardial infarction
M. Barton, M. Husmann
Eur Heart J 28, 2950, 2007

Curriculum: Atherosklerotische Gefässerkrankungen und Stickstoffmonoxid (NO): Die wachsende Bedeutung von hoher Lebenserwartung und Übergewicht für die Klinik
M. Husmann, M. Keller, M. Barton
Swiss Medical Forum 50, 1008-1011, 2007

Impaired vascular function in normoglycemic mice prone to autoimmune diabetes: Role of nitric oxide
T. Traupe, P.C. Nett, B. Frank, L. Tornillo, R. Hofmann-Lehmann, L.M. Terracciano, M. Barton
Eur J Pharmacol 557,161-167, 2007

Atherosklerotische Gefässerkrankungen und Stickstoffmonoxid (NO): Die wachsende Bedeutung
von hoher Lebenserwartung und Übergewicht für die Klinik

M. Husmann, M. Keller, M. Barton
Swiss Medical Forum 50, 1008-1011, 2007

Fat intake modifies vascular responsiveness and receptor expression of vasoconstrictors: Implications for diet-induced obesity
A.L. Mundy, E. Haas, I. Bhattacharya, C.C. Widmer, M. Kretz, R. Hofmann-Lehmann, R. Minotti, M. Barton
Cardiovasc Res 73, 368-375, 2007

Curriculum: Artériopathies athérosclérotique et monoxyde d’azote (NO) : l’importance clinique d’une espérance de vie plus longue et l’obésité
M. Husmann, M. Keller, M. Barton
Forum Médical Suisse 50, 1008-1011, 2007

Vaskuläre Interaktion zwischen Insulin und LDL Cholesterin
E. Haas, R. Minotti, C. Raselli, A. Hoehn, M. Barton
Dtsch Med Wochensch 132, 20, 2007

Endothelin stimulates vascular hydroxyl radical formation: effect of obesity
A.L. Mundy, E. Haas, I. Bhattacharya, C.C. Widmer, M. Kretz, K. Baumann, M. Barton
Am J Physiol Regul Integr Comp Physiol  293, R2218-R2224, 2007

Transcriptional regulation of vascular bone morphogenetic protein by endothelin receptors in early autoimmune diabetes mellitus
P.C. Nett, J. Ortmann, J. Celeiro, E. Haas, R. Hofmann-Lehmann, L. Tornillo, L.M. Terraciano, M. Barton
Life Sci 78, 2213-2218, 2006

Gender differences of cardiovascular disease: new perspectives for estrogen receptor signaling
M.R. Meyer, E. Haas, M. Barton
Hypertension 47, 1019-26, 2006

Downregulation of renal endothelin-converting enzyme 2 expression in early autoimmune diabetes
J. Ortmann, P.C. Nett, J. Celeiro, R. Hofmann-Lehmann, L. Tornillo, L.M. Terraciano, M. Barton
Exp Biol Med 231, 1030-1033, 2006

Endothelin inhibition delays onset of hyperglycemia and associated vascular injury in type I diabetes: evidence
for endothelin release by pancreatic islet β-cells.

J. Ortmann, P.C. Nett, J. Celeiro, T. Traupe, L. Tornillo, R. Hofmann-Lehmann, E. Haas, B. Frank, L.M. Terraciano, M. Barton
Biochem Biophys Res Commun 334, 689-695, 2005

Upregulation of vascular ETB receptor gene expression after chronic ETA receptor blockade in prediabetic NOD mice
J. Ortmann, T. Traupe, P. Nett, J. Celeiro, R. Hofmann-Lehmann, M. Lange, W. Vetter, M. Barton
J Cardiovasc Pharmacol 44, S105-S108, 2004

Obesity-associated activation of angiotensin and endothelin in the cardiovascular system
M. Barton, R. Carmona, J. Ortmann, J.E. Krieger, T. Traupe
Int J Biochem Cell Biol 35, 826-837, 2003

Cardiovascular consequences of the obesity pandemic: need for action
M. Barton, J. Furrer
Exp Opin Invest Drugs 12, 1757-1759, 2003

Effects of obesity on endothelium-dependent reactivity during acute nitric oxide inhibition: modulatory role of endothelin
T. Traupe, L.V. d'Uscio, K. Muenter, H. Morawietz, W. Vetter, M. Barton
Clin Sci (Lond) 103 (Suppl. 48), 13S-15S, 2002

Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression
T. Traupe, M. Lang, W. Goettsch, K. Münter, H. Morawietz, W. Vetter, M. Barton
J Hypertens 20, 2239-2245, 2002

Postmenopausal hormone-replacement therapy
M. Barton, R.K. Dubey
N Engl J Med 346, 63-65, 2002

Acute effects of 17β-oestradiol on functional activity of endothelin-converting enzymes in human arteries and veins
A. Heigl, M. Lachat, T. Lattmann, T. Luscher, M. Barton
Clin Sci (Lond) 103(S), 438S-441S, 2002

Estrogen and apoptosis in atherosclerosis
M. Barton, M.M. Kockx
Midlife Health - Current Concepts and Challenges for the Future, Samioe G, Skouby S, (Eds.). Proceedings of the
5th European Congress on Menopause, Copenhagen, Denmark, July 1-5, 2000
Elsevier International Congress Series, 81-93, 2002

Postmenopausal estrogen replacement therapy and atherosclerosis: Can current compounds provide cardiovascular protection?
M. Barton
Exp Opin Invest Drugs 20, 789-809, 2001

Hypertension, diabetes mellitus, hypercholesterolemia and endothelin B receptor-mediated renal nitric oxide release
M. Barton, L.V. d'Uscio
Circulation 101; e228-e229, 2000

Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo.
Evidence for a regulatory role of endothelin

M. Barton, R. Carmona, H. Morawietz, L.V. d'Uscio, W. Goettsch, H. Hillen, C.C. Haudenschild,
J.E. Krieger, K. Münter, T. Lattmann, T.F. Luscher, S. Shaw
Hypertension 35, 329-336, 2000

Sex and NO - beyond regulation of vasomotor tone
M. Barton
Cardiovasc Res 46, 20-23, 2000

Estrogen and vascular resistance
M. Barton, T.F. Luscher
Curr Opin Endocrinol Diabet 6, 218-224, 1999

Vascular effects of estrogens: rapid actions, novel mechanisms, and potential therapeutic implications
M. Barton
Acta Pharmacol Sin 20, 682-690, 1999

Vascular effect of estrogen
E. Wight, M. Barton, E. Espinosa, T. Luscher.
In: Menopause and the Heart (T.B. Clarkson, P. Collins, Eds), Taylor & Francis, Philadelphia, 1, 1-7, 1999

17β-Estradiol acutely improves endothelium-dependent relaxation to bradykinin in isolated human coronary arteries
M. Barton, J. Cremer, A. Mügge
Eur J Pharmacol 362, 73-76, 1998

Contractile responses to histamine, serotonin, and angiotensin II are impaired by 17β-estradiol in human internal mammary arteries in vitro
A. Mügge, M. Barton, H.G. Fieguth, M. Riedel
Pharmacology 54, 162-168, 1997

Gefässprotektion durch Oestrogene. Wirkungen in vitro und in vivo - Mechanismen und klinische Implikationen
M. Barton, E. Wright, D.D. Do, Z. Yang, E. Espinosa, U. Arnet, T.F. Luscher
Schweiz Rundsch Med (PRAXIS) 86, 129-137, 1997

17β-Oestradiol inhibits growth of human vascular smooth muscle: similar effects in cells from females and males
Z. Yang, D.D. Do, E. Espinosa, M. Barton, A. Arnet, T. F. Luscher
J Cardiovasc Pharmacol 28 (Suppl. 5), S34-S39, 1996

Wirkungen natürlicher Oestrogene auf die Gefässwand: Molekulare Mechanismen und klinische Implikationen
T.F. Luscher, M. Barton, E. Wight, E. Espinosa, Z. Yang
Schweiz Med Wschr 126, 1748-1755, 1996

Endothelium-independent relaxation by 17β-oestradiol of human coronary arteries in vitro
A. Mügge, M. Riedel, M. Barton, M. Kuhn, P.R. Lichtlen
Cardiovasc Res 27, 1939-1942, 1993

17β-Oestradiol dilates both human internal and coronary arteries by an endothelium-independent mechanism.
M. Barton, M. Riedel, A. Mügge
Naunyn-Schmiedeberg's Arch Pharmacol 347, 43, 1993